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Refugee Health Profiles 
 
The refugee health profiles found on this page provide key health and cultural information for specific 
refugee groups resettling in the United States. Information is gathered from the World Health 
Organization (WHO), International Organization for Migration (IOM), the United Nations High 
Commissioner for Refugees (UNHCR), US Department of State, and other sources to provide information 
that will help resettlement agencies, clinicians, and public health providers facilitate appropriate medical 
screening and interventions for refugee groups. 
Each profile includes sections that cover some of these topics: 
 Priority Health Conditions 
 Background 
 Population Movements 
 Health Care and Conditions in Camps and/or Urban Settings 
 Medical Screening of US-bound Refugees 
 Post-Arrival Medical Screening 
 Health Information 
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Priority Health Conditions 
Available data indicate that the health conditions listed below are priority health conditions that 
healthcare providers should consider when caring for or assisting Congolese refugees.  These conditions 
are considered more prevalent among this population. 
 Parasitic infections [link to parasitic infections section (page 18)] 
 Malaria [link to malaria section (page 13)] 
 Mental health [link to mental health section (page 24)] 
 Sexual and gender-based violence [link to SGBV section (page 10)] 
Background 
History of Conflict 
The Democratic Republic of the Congo (DRC, formerly known as Zaire) is located in central Africa and 
is the largest country by land mass in sub-Saharan Africa (1). For nearly 2 decades, DRC has been 
divided by armed conflict as a result of the First and Second Congo Wars (1996–1997 and 1998–2003,) 
and the Kivu Conflicts in eastern DRC (2004–present).  
Following the Rwandan genocide in 1994, millions of Rwandan refugees flooded into the eastern DRC. 
In 1996, Rwanda and Uganda invaded eastern DRC in an effort to locate the remaining perpetrators of the 
genocide, who were believed to be hiding in camps there. A coalition comprised of the Ugandan and 
Rwandan armies, along with Congolese opposition leader Laurent Kabila, eventually defeated Congolese 
dictator Mobutu Sese Seko and his army, and Laurent Kabila became president of DRC, ending the First 
Congo War in 1997. In 1998, President Kabila ordered Rwandan and Ugandan forces to leave the eastern 
DRC, fearing invasion of the resource-rich territory by the 2 regional powers (1). This move sparked the 
beginning of the Second Congo War. With the involvement of 9 African countries and more than 20 
armed militia groups, the Second Congo War is often referred to as “Africa’s World War” and is 
considered to be the deadliest global conflict since World War II (2).  
Despite the official end of the Second Congo War in 2003, various rebel groups and rogue elements of the 
Congolese army continue to commit serious human rights abuses in eastern DRC, primarily in the 
provinces of North and South Kivu, Orientale, and Katanga (2). Kivu province is ethnically diverse, with 
groups having a history of persecution (primarily the Banyamulenge and Tutsi) making up the majority in 
the region (2). The Banyamulenge, Congolese of Rwandan origin, have faced a long history of 
discrimination in DRC and, along with ethnic Tutsi and Hutu from Rwanda, are often denied citizenship 
and other rights. These groups have also been discriminated against based on their perceived association 
with Rwandan-backed rebel groups, which many blame for the unrest in the region (2). Other groups, 
such as the Bembe and Bashi, have also faced persecution on a smaller scale due to their large presence in 
the conflict area. The ongoing unrest and instability in DRC has been described by the United Nations as 




one of the world’s worst humanitarian crises and continues to cause hundreds of thousands of displaced 
persons to seek refuge in neighboring countries, including Burundi, Rwanda, Tanzania, and Uganda (2).  
Figure 1: Location of the Democratic Republic of Congo, Burundi, Rwanda, Tanzania, and Uganda 
 
Source: Division of Global Migration and Quarantine (DGMQ), CDC 
Language and Literacy 
While French is the official language of DRC and 4 national languages are considered to be primary 
languages (Lingala, Kiswahili, Kikongo, and Tshiluba) (1), the majority of refugees resettling through the 
United States Refugee Admissions Program (USRAP) will speak Kinyarwanda, because they are from 
eastern DRC (2). Many Congolese refugees are multilingual, speaking their native language as well as 
Kiswahili or other regional languages. Refugees are often exposed to English through school and the 
media; however, proficiency in English is expected to be minimal. Data from surveys conducted by the 
Resettlement Support Center in Africa (RSC-Africa) show that 59% of Congolese refugees have no oral 
English skills and an even greater percentage have no ability to read (65%) or write (66%) in English (3). 
Most Congolese adults arriving through the USRAP will not have had access to secondary education. 
Data from RSC-Africa show that 70% of Congolese over 18 years of age reported not having a high 
school diploma or higher level of education. Similar results from an assessment of 416 refugees, 
conducted by the Centers for Disease Control and Prevention (CDC) and the International Organization of 




Migration (IOM) (unpublished data), show that 14% of refugees in Rwanda had no formal education at 
all, 54% had some primary schooling, 31% had a high school diploma, and 1% had a university degree. It 
is known that girls attend schools at lower rates in DRC, so it is likely that the majority of refugees with 
no primary or high school education and low literacy levels are female. 
Religious Beliefs 
Approximately 70% of the general population in DRC is Christian and refugees being referred for US 
resettlement are overwhelmingly Christian (95%), with 80% of those Christians identifying as Protestant 
(2). Of these, a large majority identify as Pentecostal and Seventh Day Adventists. Approximately 4% of 
refugees identify as Muslim. Few refugees follow indigenous beliefs exclusively; however, traditional 
belief systems are sometimes incorporated into religious practices and are familiar to a majority of 
Congolese (2). 
Family and Kinship 
A typical Congolese household includes not only immediate family, but generally also includes extended 
family and sometimes those not related by blood. The Congolese interpret family in a much broader sense 
than Westerners. Children are considered a sign of prosperity and good fortune for the community, so 
families are often large, with a fertility rate of 5 children born per Congolese woman (1). Care and 
discipline of children are considered shared responsibilities of the whole community, therefore it is not 
uncommon for adults who are not biologically related to a child to correct poor behavior and provide 
input on their upbringing.  
Gender Roles 
In the past, gender roles have typically been well defined, with men protecting and providing for the 
family and women traditionally taking care of children and tending to household chores. However, as the 
conflict in DRC expanded in the mid-1990’s, traditional roles began to change as women were forced to 
become the primary source of financial support for the family. It is no longer uncommon for Congolese 
women to work outside of the home, usually selling handcrafts or running small businesses. While 
education is accessible to both genders in urban areas, there continues to be a male bias and women still 
tend to remain unequal in most sectors of society (2).  
Cultural Approach to Health Care 
Western medicine is generally well-received in Congolese culture, although significant barriers (e.g., 
geographic location to health centers, high cost) often prevent access to quality healthcare and treatment 
within the DRC (2). As a result, the Congolese may seek traditional medicines in lieu of, or in 
combination with, Western therapies. Medical infrastructure is limited mostly to urban areas and care is 
only delivered after payment in cash, therefore an inability to access or pay for care may lead patients to 
use herbal medicines or consult with traditional spiritual healers (Feticheur) to resolve illnesses. Christian 
Congolese are known to rely heavily on prayer (2). Mental illness is often considered a curse (sometimes 
believed to be caused by supernatural elements or the result of witchcraft) and is not openly discussed. 
For more information on mental health, refer to the mental health section of this profile. 
Additional Resources 
For more information about the orientation, resettlement and adjustment of Congolese refugees, visit the 
Cultural Orientation Resource Center, which is maintained by the organization of the same name. 





Movement Out of DRC to Burundi, Rwanda, Tanzania, and Uganda 
Since January 2013, UNHCR reports that more than 400,000 Congolese nationals have sought refuge 
outside of DRC (4). Although Congolese refugees reside in many different countries in sub-Saharan 
Africa, the 4 primary host countries providing asylum to Congolese refugees are Uganda (113,000), 
Rwanda (68,000), Tanzania (59,000), and Burundi (38,000) (4). There are several large refugee camps or 
settlement areas within each host country, with Nakivale (Uganda) and Nyarugusu (Tanzania) holding the 
largest number of Congolese refugees in the “Great Lakes” region of central/eastern Africa (Figure 2). 
The majority of Congolese refugees from DRC live in camp-based settings; however, a growing number 
in Rwanda and Uganda are now living in settlements in urban settings as encampment policies are lifted 
and host governments are allowing more refugees to move freely within the country. For example, 
Uganda has experienced a fivefold increase in the number of refugees living in Kampala from 2007–
2013, with 48,000 Congolese now living in Uganda’s capital city. In the beginning of 2012, an escalation 
of conflict in the Kivu region of DRC resulted in almost 70,000 new refugee arrivals into camps in 
Burundi, Rwanda, and Uganda. As fighting continues, the numbers are expected to grow. 




Figure 2. Location and size of major refugee populations in Burundi, Rwanda, Tanzania, and Uganda, 
2013* 
 
Source: DGMQ, CDC, and UNHCR’s Health Information System (HIS) 
* Refugee population numbers include refugees from multiple countries, not exclusively DRC. Some locations are refugee camps 
and others are urban refugee populations.  









Resettlement of Congolese Refugees in the United States 
In 2000, the USRAP began resettling small numbers of Congolese refugees in the United States, with the 
largest caseloads coming from Tanzania (5). From 2008–2013, approximately 11,000 Congolese refugees 
arrived in the United States from 36 countries (Figure 3). Refugees have been resettled in multiple states, 
with Texas, Arizona, Kentucky, and New York each receiving ≥6% of total arrivals (Figure 4). However, 
once refugees arrive in a state, they are free to relocate elsewhere, and secondary migration to join an 
already established Congolese community is common. Most (55%) Congolese refugees who resettled in 
the United States during this period were young adults aged 15–44 years and 40% were children under 15 
years old (Figure 5). Because of the long history of violence in DRC and the recent escalation of conflict 
in the Kivu region, durable solutions such as repatriation do not appear likely for Congolese refugees 
anytime in the near future. In 2012, the US Bureau of Population, Refugees, and Migration (PRM) 
announced a new initiative to resettle approximately 50,000 Congolese refugees in the United States over 
the next 5 years (2013–2018).  
Figure 3: Congolese refugee arrivals in the US, 2008–2013 (n=10,960) 
 






















































































































* The remaining 4,194 Congolese refugees were resettled in other states. Source: CDC, DGMQ, EDN  
Figure 5: Age distribution for Congolese refugees originating from refugee camps in Burundi, 
Rwanda, Tanzania, and Uganda, 2008–2012 (N=4,938) 
 
Source: CDC, DGMQ, EDN 




Healthcare Access and Conditions in Refugee Camps 
Refugee camps in Burundi, Rwanda, Tanzania, and Uganda (the 4 top countries sending Congolese 
refugees to the United States) each have different nongovernmental organizations (NGOs) that provide 
inpatient and outpatient medical care and community health education to camp residents. UNHCR 
collects health information in refugee camps and reports this information in their Health Information 
System (HIS). Some services offered by the NGOs include pediatrics and integrated management of 
childhood illness, reproductive health, psychiatric consultation, emergency medical services and referrals, 
basic laboratory services, tuberculosis (TB) management (directly observed therapy with first-line 
agents), voluntary testing and counseling for human immunodeficiency virus/acquired immunodeficiency 
syndrome (HIV/AIDS) with referral services for antiretroviral treatment, and nutrition promotion. 
Immunizations 
Burundi, Rwanda, Tanzania, and Uganda administer vaccines in line with the World Health Organizations 
(WHO) Expanded Program on Immunization. Precise estimates of vaccine coverage in camps are difficult 
to obtain because the exact number of people living in the camps is not known. Supplemental mass 
immunization campaigns are also carried out by NGOs following announcements from the host country 
governments. If appropriate documentation from the refugee is available, the vaccinations given to that 
person will be noted on the US Department of State’s form DS-3025, which is included in the health 
information packet provided to each refugee before he or she departs. DS forms are the forms used by 
physicians to complete the overseas medical screening examinations. The health information packet is 
supplied by IOM and contains the refugees’ medical screening examination information for reference 
upon the refugees’ arrival in the United States. Additionally, IOM’s Pre-Departure Medical Screening 
Form will note vaccination information for individual refugees. All vaccination information will also 
appear in CDC’s Electronic Disease Notification system (EDN).  
Reproductive Health  
Birthrates in refugee camps in Rwanda, Tanzania, and Uganda vary considerably (Figure 6). There are no 
data available for Burundi. The percent of births that are attended by a skilled midwife or a health worker 
with midwifery skills varies depending on the camp and country. In 2012 the percentages of births 
attended by a skilled attendant in the refugee camps were: 100% for Burundi, 92% for Rwanda, 100% for 
Tanzania, and 93% for Uganda (6). It should be noted that the above statistics apply to refugees from 
multiple countries that are living in the camps in Burundi, Rwanda, Tanzania, and Uganda, not refugees 
exclusively from DRC. Additionally, Congolese refugees may not feel comfortable discussing sexuality 
and gynecological issues with non-family members, especially male clinicians. 




Figure 6: Crude birth rates in refugee camps in Rwanda, Tanzania, and Uganda by month, 2009–2012 
 
Source: Office of the United Nations High Commissioner for Refugees (UNHCR), Health Information System (HIS) 
Sexual- and Gender-Based Violence 
The conflict in eastern DRC has been marked by numerous human rights abuses, including sexual and 
gender-based violence (SGBV). Reports include gang rapes, sexual slavery, purposeful mutilation of 
women’s genitalia, and killing of rape victims (7). One study estimated that 48 women are raped every 
hour in DRC, which is a little over 1,150 women a day (8). According to a population-based study 
conducted in the eastern DRC in 2010, rates of reported sexual violence were 40% among women, and 
24% among men. In addition to sexual violence, 20% of the adult population in the study reported serving 
as combatants at some point in their lifetime, the majority of whom reported being conscripted into armed 
groups (9). The brutality of such sexual violence has resulted in unprecedented rates of trauma, physical 
injury including fistula, pregnancy, infertility, genital mutilation, and HIV/AIDS and other sexually 
transmitted diseases. 50% of rape victims in the DRC are believed not to have access to medical treatment 
(10). 
The threat of SGBV is also present in the refugee camp environment, particularly where women and girls 
must travel on foot outside the camps to collect firewood, risking harassment, rape, and other abuses. 
Service providers in Rwanda noted that limited work opportunities force some women and girls into 
abusive relationships or “survival sex,” i.e., coerced sex in exchange for temporary access to food, shelter, 
or protection. Additionally, a refugee’s access to mental health services in these camps is often extremely 
limited; in 1 camp, 1 psychological nurse may be responsible for 16,000 refugees (11). 
 
The psychosocial consequences of being raped are devastating. Fear, shame, insomnia, and nightmares 
are frequently noted among sexual violence survivors. In eastern DRC, rape is highly stigmatized and 
social problems include spousal abandonment, inability to marry, and ostracism by the community. 
Spousal and community abandonment can lead to isolation and homelessness (12). 
However, despite experiences of SGBV being common within the Congolese refugee population, SGBV 
is an extremely sensitive issue, and associated with much shame. Service providers with experience 
treating these patients recommend that public health officials not ask intrusive personal questions upon 
the patient’s initial screening and early visits, but wait until the patient trusts the service providers.  




While much attention has been paid to sexual violence allegedly committed by paramilitary personnel and 
soldiers, intimate partner sexual violence (IPSV) has been less visible. A Demographic and Health Survey 
conducted in 2007 suggests that this is a particularly large problem in the DRC, with approximately 35% 
of women reporting IPSV (13). From a nationally representative household survey conducted in all 11 
provinces of DRC in 2010, the total number of women estimated to have suffered IPSV ranged from 3.07 
million to 3.37 million, with the number of women reporting IPSV roughly 1.8 times the number of 
women reporting rape (14). This result is in line with international research indicating that intimate 
partner sexual violence is the most pervasive form of violence against women (15). 
Female Genital Cutting 
The practice of female genital cutting (FGC, also referred to as female genital mutilation), which is the 
partial or total removal of the external female genitalia or other injury to the female genital organs for 
cultural, religious, or non-therapeutic reasons, is known to exist in the DRC, but current data on the 
prevalence of FGC are not available (WHO). However, in a 2007 report, UNICEF stated that the 
prevalence of FGC in the DRC was estimated to be less than 5% (16). 
Medical Screening of US-bound Refugees 
Congolese refugees who have been identified for resettlement in the United States receive medical 
assessments (Figure 7). Some assessments occur several months prior to the refugees’ departure and some 
occur immediately before departure to the United States. 
Figure 7: Medical assessment of United States-bound Congolese refugees 
 
* Class B1 TB refers to TB fully treated by directly observed therapy, or abnormal chest x-ray with negative sputum smears and 
cultures, or extrapulmonary TB. 
Overseas Medical Examination 
An overseas medical examination is mandatory for all refugees resettling in the United States and must be 
performed according to CDC’s Technical Instructions. The purpose of the medical examination is to 
identify applicants with inadmissible health-related conditions, and they are performed by panel 
physicians who are selected by US Department of State consular officials. CDC provides the regulatory 
and technical oversight and training for all panel physicians. Information collected during the refugee 
Overseas Medical 
Examination
• 6 months before 
departure
• All refugees





• 3 weeks before 
departure
• Refugees with Class 
B1 TB*
Fit to Fly Pre-
Embarkation Checks














overseas medical examination is reported to EDN and is available to state refugee health programs in the 
states where the refugees are resettled. 
 
Refugees do not have to receive any vaccines before they are admitted into the United States. Vaccines 
given to Congolese refugees during the overseas medical examination vary depending on the country 
where they reside during the examination.  
 
Pre-Departure Medical Screening 
Congolese refugees receive a pre-departure medical screening about 3 weeks before leaving for the 
United States if they have been previously diagnosed with class B1 TB (TB fully treated using directly 
observed therapy, or abnormal chest x-ray with negative sputum smears and cultures, or extrapulmonary 
TB). The screening includes a repeat physical examination with a focus on TB signs and symptoms, chest 
x-ray, and sputum collection for acid-fast bacilli smear microscopy. 
Pre-Embarkation Checks 
IOM clinicians perform 2 pre-embarkation checks within 48 hours of the refugee’s departure for the 
United States to assess his or her fitness for travel. During this assessment, the clinician administers 
presumptive therapy for intestinal parasites (worms) and malaria. Presumptive therapy is treatment of 
individuals who have a high likelihood of asymptomatic or sub-clinical infection without, or prior to, 
results from confirmatory laboratory tests. 
Congolese refugees departing from Kenya, Tanzania, Uganda, and Rwanda receive pre-departure 
treatment for soil-transmitted helminths, schistosomiasis, and malaria according to current CDC guidance. 
Except when contraindicated, refugees are treated for soil-transmitted helminths with a single dose of 
albendazole, schistosomiasis with standard dose of praziquantel (divided into two doses for better 
tolerance), and malaria with a 6-dose schedule of artemether-lumefantrine. Management of Strongyloides 
in Congolese refugees is deferred until the refugee’s arrival in the United States. Guidance for this is 
available in the Domestic Intestinal Parasite Screening Guidelines. Refugees from sub-Saharan Africa are 
normally given presumptive treatment for infection with Strongyloides with ivermectin; however, since 
DRC is a Loa loa-endemic country, Congolese refugees should not receive presumptive ivermectin for 
strongyloidiasis prior to departure because of the risk of encephalopathy.  
Information on presumptive therapy for intestinal parasites will be noted on IOM’s Pre-Departure 
Medical Screening Form, which is included in the packet provided to each refugee before he or she 
departs. Information on presumptive therapy for intestinal parasites given to refugees will also appear in 
EDN.  
Surveillance 
Active surveillance for communicable diseases of public health significance (such as TB) takes place 
through all phases of overseas medical processing. This surveillance is designed to identify refugees with 
conditions that may result in deferred travel or other interventions. In addition, when disease outbreaks 
occur in the camps, IOM coordinates with the local implementing partners to identify refugees in the 
resettlement program who may be affected. Depending on the nature of the disease outbreak, various 
interventions may then be used, such as deferral of travel, additional vaccinations, and presumptive or 
directed therapy. 




Post-Arrival Medical Screening 
Once refugees have arrived in the United States, CDC recommends that they receive a post-arrival 
medical screening (domestic medical screening) within 30 days. The Office of Refugee Resettlement 
reimburses providers for screenings conducted during the first 90 days after arrival. The purpose of these 
more comprehensive examinations is to identify conditions for which refugees may not have been 
screened during their overseas medical examinations. The examinations also introduce refugees to the US 
healthcare system. CDC provides guidelines and recommendations while state health departments oversee 
and administer the domestic medical screenings. State refugee health programs determine who conducts 
the examinations within their jurisdiction; these may be performed by health department personnel or 
private physicians. Data from the screenings are collected by most state health departments. 
Health Conditions for Healthcare Providers to Consider in Post-Arrival Medical Screening 
of Congolese Refugees 
In addition to the standard guidelines for post-arrival medical screening of newly arriving refugees, 
clinicians should consider the following health conditions. 
Malaria 
According to the current United States domestic screening guidelines for malaria, refugees who have 
received presumptive treatment prior to departure need no further evaluation for malaria unless they 
demonstrate signs or symptoms of infection. CDC recommends that Congolese refugees originating from 
other sub-Saharan African countries who have not received pre-departure therapy either receive 
presumptive treatment when they arrive or have laboratory screening with a blood smear.  
Strongyloidiasis  
CDC currently recommends that all United States-bound Congolese refugees either be presumptively 
treated OR tested and treated (if positive) for strongyloidiasis after arrival in the United States. Currently, 
only Congolese refugees departing from Kenya receive pre-departure treatment for strongyloidiasis. 
The treatment of choice for Strongyloides infection is ivermectin, a single dose for 2 consecutive days. 
However, the management of Strongyloides infection in the Congolese refugees is complicated by the 
possibility of co-infection with the parasite Loa loa, also known as “eye worm.” Persons with a high 
blood level (microfilarial load) of Loa loa who are given ivermectin therapy can develop severe 
encephalopathy. Although this is rare, CDC recommends that a patient originating from, or transiting 
through, a Loa loa endemic country be tested prior to ivermectin use to ensure that he or she does not 
have a high microfilarial load. Please refer to the list of Loa loa-endemic countries.  
Use one of these three approaches to address Strongyloides infection in Congolese who are at risk of co-
infection with Loa loa infection: 
1. Presumptive treatment with ivermectin after testing for Loa loa 
To diagnose Loa loa, a daytime blood smear (thick and thin, same test as for malaria) can be done 
between 10 a.m. and 2 p.m. If there are no Loa loa parasites observed, ivermectin may be safely 
used to presumptively treat the refugee.  
2. Presumptive treatment with “high-dose” albendazole without testing for Loa loa 




Presumptively treat refugees with “high-dose” albendazole without testing for Loa loa infection. 
The dosing recommended for treatment of Strongyloides infection is albendazole 400 mg twice a 
day for 7 days.  
3. Test for Strongyloides, Loa loa and treatment if positive 
Test the refugee for Strongyloides infection and only treat (for Strongyloides) those whose results 
are positive. Serology is the most sensitive test for detecting Strongyloides infection. Stool ova 
and parasite examination or stool agar culture may be used as additional tests but should not be 
used alone because of poor sensitivity. Those with positive test result (for Strongyloides) could 
either be treated with ivermectin (if a daytime blood smear is negative as described above) or 
with the 7-day course of albendazole.  
For more information, please see the Domestic Intestinal Parasite Guidelines for refugees. 
Schistosomiasis 
Refugees originating in sub-Saharan Africa without a contraindication receive a treatment dose of 
praziquantel prior to departure, which presumptively treats a majority of infected individuals. Currently, 
those Congolese refugees from the asylum countries of Tanzania, Rwanda, Uganda, and South Africa 
should be receiving praziquantel prior to departure. However, a treatment dose of praziquantel is not 
100% effective and any refugee with signs or symptoms of active disease, most often, a persistently 
elevated eosinophil count, may need further evaluation for schistosomiasis. Please see Presumptive 
Treatment and Screening for Strongyloidiasis, Schistosomiasis, and Infections Caused by Soil-
Transmitted Helminths for Refugees for additional information on domestic medical screening. 
Filariasis 
The filarial diseases are caused by nematodes transmitted to humans, most commonly through black flies 
and mosquitoes. The 3 most common infections, all endemic to DRC, are loiasis, lymphatic filariasis, and 
onchocerciasis. The filarial infections are common in the DRC and co-infection is common.  They may 
persist for a decade or more and some of the complications may be permanent.  Most people infected with 
these nematodes will never develop symptoms.  The most common clinical sign in refugees is a persistent 
elevated eosinophil count. Therefore, these parasites need to be considered in Congolese refugees with a 
persistent elevated eosinophil count and in those with symptoms more specific to each nematode.  
Loiasis, (also known as “eye worm”), caused by the parasitic roundworm Loa loa, is transmitted 
by red (chrysops) flies and is endemic through most of DRC although it is particularly common in 
certain focal areas. Most infected individuals have no symptoms, but common clinical 
manifestations include an increased eosinophil count, recurrent episodes of transient itchy 
swellings (local angioedema) usually found on the limbs or near joints and sometimes referred to 
as “Calabar swellings”, and “eye worm”. Eye worm is the visible migration of the adult worm 
across the surface of the eye which may be associated with eye congestion, itching, pain, and 
light sensitivity. Other symptoms include generalized itching, hives, muscle pains, joint aches, 
fatigue, and the visible migrating worm under the surface of the skin. Infection does occur in the 
absence of an elevated eosinophil count.   
Lymphatic filariasis, most commonly caused by the nematode Wuchereria bancrofti, is 
transmitted to humans by mosquito vectors. Lymphatic filariasis is distributed throughout DRC as 




well as all major East African countries of asylum. Most infected persons will never develop 
symptoms. The most common clinical manifestations are a persistently elevated eosinophil count, 
and a lymphedema that usually affects the legs but also occurs in the arms, breasts, and genitalia 
(especially hydrocele or swelling of the scrotum in males).  Infection does occur in the absence of 
an elevated eosinophil count.  When the swelling is accompanied by hardening and thickening of 
the skin it is commonly referred to as elephantiasis. This condition predisposes patients to 
bacterial infections. 
Onchocerciasis, caused by Onchocerca volvulus, is transmitted to humans through the bite of a 
blackfly. Onchocerciasis is found throughout most of DRC as well as in areas of Burundi, 
Rwanda, Tanzania, and Uganda. Common clinical manifestations include generalized itching, 
nodules under the skin, rashes and, most concerning, visual changes (commonly known as “river 
blindness”). When larva die within the eye they initially cause reversible lesions of the cornea. 
However, with time they may result in permanent clouding of the cornea and blindness. In 
addition, inflammation of the optic nerve may occur, resulting in vision loss.  Although an 
elevated eosinophil count is common, infection does occur in the absence of an elevated count.   
Diagnosis and treatment of filariasis is complicated and beyond the scope of this document.  Further 
information on each parasite may be obtained at the CDC Division of Parasitic Diseases.  CDC also offers 
diagnostic and treatment assistance. 
African Trypanosomiasis 
African trypanosomiasis, also known as sleeping sickness, is an insect borne infection transmitted by 
tsetse flies.  It is caused by microscopic parasites of the species Trypanosoma brucei. There are two 
subspecies of T. brucei, T.b. Rhodensiense (East African) and T.b. gambiense (West African).  Refugees 
from the DRC may be at risk of West African trypanosomiasis (Trypanosoma brucei gambiense) where 
West African sleeping sickness is endemic, although most of the refugees report being from non-endemic 
areas of DRC.  Depending on migration route, refugees may also be at risk for T.b. Rhodensiense which is 
most endemic in Tanzania, Uganda, Malawi and Zambia.  T.b. Rhodensiense is less common and has a 
more acute onset and would be observed at the time of migration or shortly following arrival and would 
be characterized by fevers, headache, muscle and joint aches, enlarged lymph nodes and is frequently 
accompanied by a large sore (a chancre) at the bite site.  There is relatively rapid clinical decline without 
treatment with mental disorientation, other neurologic symptoms, coma resulting in death within months. 
T.b. gambiense, more common and of greater concern in refugees, since it is more common and may be 
more insidious occurring months to years after after infection.  Symptoms of West African 
trypanosomiasis typically emerge and include fever, rash, swelling of the hands and face, headaches, 
fatigue, myalgias and arthralgias, pruritis, and lymphadenopathy. As disease progresses, weight loss 
ensues with progressive confusion, personality changes, daytime sleepiness with nighttime sleep 
disturbances, and other neurologic signs and symptoms such as paralysis, ataxia, and balance problems. If 
left untreated, neurologic symptoms will progress until eventually death occurs, usually years after initial 
infection.  
The diagnosis should be considered in any refugee with potential exposure and unexplained signs or 
symptoms such as weight loss and neurologic decline.  




More information on the biology, diagnosis, and treatment of these diseases may be found on the CDC 
Parasitic diseases website.  CDC also offers diagnostic and treatment assistance. 
Syphilis 
Given the low prevalence of syphilis in the Congolese refugee population (Table 5), screening for syphilis 
should follow the current CDC domestic refugee medical screening guidelines. That is, providers should 
rely on the results of the pre-departure testing, if it is available.  
Repeat screening should be done domestically with a nontreponemal test (e.g., Venereal Disease Research 
Laboratory [VDRL] or rapid plasma reagin [RPR]) in the following situations:  
 For all refugees ≥15 years old if overseas results are not available. 
 For children <15 years old who are at risk (i.e., mother who tests positive for syphilis) 
should be evaluated according to the Congenital Syphilis section of the CDC Sexually 
Transmitted Diseases Treatment Guidelines, 2010.  
 Any refugee who has a history of sexual assault 
Refugees with positive nontreponemal screening test results should have confirmatory treponemal testing.  
HIV Infection 
HIV testing is offered to refugees by many state health departments. The current domestic refugee 
screening guidelines for HIV recommend universal screening of refugees after arrival. This is especially 
important since in January 2010, the requirement for HIV testing of adult refugees prior to US 
resettlement was removed. The known history of sexual violence in the Congolese refugee population and 
data that indicate relatively higher rates than most refugee populations reinforce the importance of HIV 
screening in Congolese refugees. 
Chlamydia and Gonorrhea 
The current Refugee Domestic Screening Guidelines for Sexually Transmitted Diseases suggest routine 
screening for chlamydia in women <25 years old who are sexually active, or testing refugees for 
chlamydia and gonorrhea if there are known risk factors or signs of infection. 
There are limited data available on rates of chlamydia and gonorrhea in Congolese refugees (Table 5). 
Given the lack of data and well-documented high rates of sexual violence, it is reasonable to extend 
screening for chlamydia and gonorrhea to both female and male adult refugees as well as any child with a 
history of sexual abuse or signs of infection (e.g., leukesterase).  
Chronic Viral Hepatitis 
The most common chronic viral hepatitis encountered in refugees is hepatitis B.  Clinicians should screen 
all Congolese refugees for chronic infection with hepatitis B virus on arrival to the U.S., as recommended 
in the CDC Guidelines for the U.S. Domestic Medical Examination for Newly Arriving Refugees. Some 
Congolese refugees may have received one or more doses of hepatitis B vaccine.  Hepatitis B surface 
antibody may be positive if measured after the first or second dose of vaccination and does not 
necessarily indicate long-term immunity. Congolese refugees generally do not receive the full hepatitis B 
series prior to migration, with the exception of refugees departing from Kenya (since September 2013). 
Even if vaccinated, refugees should be screened for hepatitis B infection if previous results are not 
available since vaccination does not protect a person with precedent infection.  If the refugee is not 




infected with hepatitis B virus, and has not received an acceptable full course of hepatitis B 
immunization, the vaccine course should be completed according to ACIP guidelines.  More information 
and guidance about hepatitis B infection and prevention in refugees is available in the domestic screening 
guidelines. There are no published or other available screening data on the prevalence of hepatitis C in 




Anemia is frequently caused by multiple factors such as nutritional deficiency (e.g., low iron intake), 
parasitic infections such as hookworm and malaria, thalassemias, and hemoglobinopathies, although it 
may indicate other underlying diseases (e.g., cancer, ulcers). There will be an expected higher rate of 
sickle cell anemia (SCA) in Congolese refugees based on available country prevalence data, and 
physicians may consider screening for SCA, especially in refugees found to have anemia. Screening may 
lead to appropriate management and monitoring of those with SCA as well as to counseling of those who 
have sickle cell trait.  
In addition, glucose-6-dehydrogenase (G-6-PD) deficiency, an enzyme deficiency, is common in certain 
populations and has been estimated to occur in 19% of the population of the DRC (17). Unlike most 
inherited hematologic disorders which result in anemia (e.g., decreased hemoglobin or change in indices 
such as MCV or RDW), G-6-PD deficiency is not evident on routine blood testing or blood smears. 
Under certain circumstances, G-6-PD deficiency may result in acute hemolytic anemia, usually after a 
refugee with this condition is exposed to certain medications, foods, or even infections. Therefore, certain 
medications with strong oxidizing potential (e.g., primaquine for malaria, dapsone) should be avoided if 
the patient’s G-6-PD status is unknown (or the patient should be tested for G-6-PD deficiency before he 
or she takes the medication). Other common oxidizing medications should also be used with caution or 
avoided in this population, including sulfa-based medications; unless the patient’s G-6-PD status is 
known.  
Alpha thalassemia should also be considered in patients with an anemia. 
Hypertension, Dyslipidemia, and Diabetes 
Routine blood pressure screening and monitoring is suggested in newly arriving Congolese refugees, as 
with all populations. Diabetes should be considered when there are risk factors (e.g., obesity) or other 
common signs are present (e.g., hyperglycemia on blood chemistry, glucosuria). Lipid screening should 
be considered according to United States’ guidelines. 





This section describes the disease burden for specific diseases among the Congolese refugee community. 
The data sources for this section include the International Organization of Migration (IOM), United 
Nations High Commissioner for Refugees (UNHCR) Health Information System (HIS), CDC’s 
Electronic Disease Notification System (EDN), a CDC pilot assessment of Congolese refugees in Rwanda 
in September 2012, and data from domestic screening exams provided by state health departments. 
Communicable Disease 
Malaria 
Although malaria is common in DRC, the rate of malaria in refugees will better reflect their country of 
asylum (Figure 8). Therefore, certain populations will have very low rates of malaria prior to migration, 
such as the Congolese in Rwanda, where most populations are located in high altitude areas which have 
no malaria transmission. Conversely, populations originating in Tanzania, Uganda, Burundi, and Zambia 
are more likely to have had more recent malaria exposure. According to refugee health screening data 
from health departments in 5 Congolese refugee-receiving states, of the 321 Congolese refugees screened, 
4 (1.2%) tested positive for malaria. For more information on malaria screening for Congolese refugees 
refer to the Health Conditions to Consider in Post-Arrival Medical Screening of Congolese Refugees: 
Malaria section of this profile. 
Figure 8: Incidence rates of confirmed malaria cases in refugee camps in Rwanda, Tanzania, Uganda, 
and by month, 2009–2012 
 
Source: Office of the United Nations High Commissioner for Refugees (UNHCR), Health Information System (HIS) 
Parasitic Infections 
Domestic medical screening data from 4 states have shown a number of parasitic infections that can be 
diagnosed in Congolese refugees (Figure 9). The following section describes some of the most common 
parasitic infections among Congolese refugees. 
Strongyloidiasis  
Strongyloidiasis is a parasitic nematode infection that is common in Congolese refugees and is 
known to persist for more than 50 years in the human host. Infection is frequently asymptomatic 
but may lead to morbidity and, when the infected individual is immunosuppressed, even result in 
death. Unlike most parasites that are unable to replicate in the human host, Strongyloides is able 




to replicate, causing infection that may persist for decades. If strongyloidiasis is not detected 
promptly after an infected refugee’s arrival, data indicate that the average time to diagnosis in the 
United States is more than 5 years after migration (18). Strongyloides hyperinfection syndrome 
may occur many years after an infected refugee migrates to a non-endemic setting, with case 
reports occurring >50 years after a refugee’s last known exposure (19, 20, 21). Hyperinfection 
syndrome, triggered when large numbers of parasites infiltrate internal organs, results in fatality 
rates exceeding 50%. The syndrome is generally induced when an individual is placed on 
corticosteroids, although other immunosuppressive conditions (such as cancer and transplant 
chemotherapeutic immunosuppression) may also trigger it (19, 21). Data from newly arrived 
Congolese refugees from 1 resettlement state found that 37.5% of 267 specimens tested positive 
(Figure 12). Testing of specimens for Strongyloides was performed if the refugee was not 
presumptively treated overseas and if a test was available at the state laboratory. For more 
information on Strongyloides screening for Congolese refugees, refer to the Health Conditions to 
Consider in Post-Arrival Medical Screening of Congolese Refugees: Strongyloidiasis section of 
this profile. 
Schistosomiasis 
Schistosomiasis, caused by S. hematobium and S. mansoni, is common in DRC populations. In 
addition, infection may be found in all countries of asylum including Burundi, Rwanda, South 
Africa, Tanzania, Uganda, and Zambia. Untreated infection generally lasts more than a decade 
but can persist up to 30 years. Schistosomiasis is associated with liver cirrhosis and resulting 
clinical complications (S. mansoni, S. japonicum), squamous cell carcinoma of the bladder (S. 
haematobium), and urinary tract obstruction and renal failure (S. haematobium). Potentially 
devastating clinical manifestations occasionally occur when the parasite egg enters a refugee’s 
systemic circulation and travels to a normally sterile site within the body, causing severe 
inflammation. Eggs may travel to any part of the body, including the brain and spinal cord, where 
the inflammatory response to the egg may cause paralysis or myelitis. Data obtained from newly 
arrived Congolese refugees from 2 resettlement states found a 5.6% seroprevalence in 1,279 
tested specimens, although not all Congolese refugees were screened for schistosomiasis (Figure 
12). Testing of specimens for schistosomiasis was done if the refugee was not presumptively 
treated overseas. For more information on schistosomiasis presumptive treatment during the Pre-
Departure Medical Screening of Congolese refugees refer to the Pre-Departure Medical 
Screening section of this profile. 




Figure 9: Parasites identified by stool ova and parasite examination in Congolese refugees during 
domestic medical examinations in 4 states from 2010–2013 (n=1,347) 
 
1 Parasites represented in the Other category include Chilomastix mesnili, Endolimax nana, Entamoeba coli, Entamoeba 
hartmanni, and Iodamoeba buetshlii. 
Source: Refugee health screening data from health departments in California, Colorado, Illinois, and New York 
Tuberculosis 
Among Congolese refugees screened under the 1991 TB Technical Instructions from 2008–2013, 
approximately 0.6% (n=31) arrived to the United States with a Class B1 TB designation (defined as TB 
fully treated using directly observed therapy, or abnormal chest x-ray [CXR] with negative sputum 
smears and cultures, or extrapulmonary TB) (Figure 10). Of those screened under the 2007 TB Technical 
Instructions from 2008–2013, 1.1% (n=56) arrived in the United States with a Class B1 designation. 
During the overseas medical examinations, tuberculin skin tests (TST) are routinely performed on 
children aged 2–14 years (whereas all adults receive chest x-rays). Children who have a positive TST and 
normal chest x-ray findings are designated as TB Class B2 LTBI (latent tuberculosis infection). From 
2008–2012, approximately 1.3% (n=66) of children examined by IOM physicians using the 2007 TB 
Technical Instructions in Burundi, Rwanda, Tanzania, and Uganda had a positive TST with >10 mm 
induration (Figure 10). During post-arrival screening exams in 4 large Congolese refugee-receiving states, 
approximately 30% (n=145) of those screened had latent TB infection, while only 1% (n=5) of those 
screened had active TB disease (Figure 11).  
Of more than 4,938 refugees screened for active TB during visa medical examinations conducted by IOM 
physicians in Burundi, Rwanda, Tanzania, and Uganda, only 1 (0.02%) was sputum smear or culture 
positive for Mycobacterium tuberculosis and completed treatment overseas. Only 26 (0.5%) Congolese 







































Figure 10: Overseas TB classifications using the 1991 TB Technical Instructions and the 2007 TB 
Technical Instructions using directly observed therapy (DOT) and cultures for Congolese refugees who 
resettled in the United States from 2008–2013 (n=4,938) 
1 TB Class B1 using the 1991 TB technical instructions is defined as having an abnormal chest radiograph suggestive of active 
tuberculosis and a negative acid-fast bacilli sputum smear.  
2 TB Class B2 using the 1991 TB technical instructions is defined as having an abnormal chest radiograph suggestive of inactive 
tuberculosis. Source: EDN 
3 TB Class B1 using the 2007 TB technical instructions is defined as having a medical history, physical exam, or chest 
radiographic findings suggestive of pulmonary TB with negative acid-fast bacilli sputum smears and cultures or having had a 
diagnosis of pulmonary TB but successfully completing directly observed therapy prior to immigration to the US. 
4 TB Class B2 using the 2007 TB technical instructions is defined as having a tuberculin skin test >= 10mm induration or a 
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Source: Refugee health screening data from health departments in California, Colorado, Illinois, and New York 
Chronic Viral Hepatitis 
The World Health Organization estimates a 5-7% prevalence of active hepatitis B virus infection in the 
region of origin for Congolese refugees. During post-arrival screening exams in 4 large Congolese 
refugee-receiving states, 6.1% (124/2,355) of Congolese refugees screened from 2010–2013 had a 
detectable serum hepatitis B surface antigen, and indicator of active hepatitis B virus (HBV) infection 
(Figure 12). Data from a pilot health assessment conducted in refugee camps in Rwanda in 2012 showed 
that 3% of 416 refugees screened were infected with HBV (unpublished CDC data). There are no data 
available on the prevalence of different viral hepatitis infections in the camps in Burundi, Tanzania, or 
Uganda. For more information on HIV testing for Congolese refugees, refer to the Health Conditions to 


































Figure 12: Communicable diseases found in Congolese refugees during domestic medical 
examinations in 6 states from 2010–2013 (n=2,355)* 
 
Source: Refugee health screening data from health departments in California, Colorado, Illinois, New York, Texas, and Indiana 
*Not all states screened for all diseases listed 
 
Sexually Transmitted Disease 
HIV 
As of January 2010, HIV testing is no longer an overseas medical examination requirement. However, 
some state health departments provide HIV testing for refugees. Among 2,355 Congolese refugees 
screened in California, Colorado, and Illinois from 2010–2013, 3.1% tested positive for HIV infection 
(Figure 12). Data from a pilot health assessment conducted in refugee camps in Rwanda in 2012 showed 
that 6% of 416 refugees screened were infected with HIV (unpublished CDC data). The higher prevalence 
of HIV in the Rwanda pilot likely reflects a prioritization of USRAP referrals for those who are most 
vulnerable and have specific health needs in the first phases of the larger resettlement effort occurring 
over the next 5 years (i.e., approximately 50,000 Congolese to be resettled during 2013–2018). Due to 
this referral priority, it is likely that the first groups of Congolese refugees arriving in the US during this 
time period will have higher rates of HIV and should be linked to HIV services immediately following 
their arrival. For more information on HIV testing for Congolese refugees, refer to the Health Conditions 
to Consider in Post-Arrival Medical Screening of Congolese Refugees: HIV Infection section of this 
profile. 
Syphilis 
Syphilis screening is an overseas medical examination requirement, and treatment is provided overseas to 
those who test positive. Among 2,355 Congolese refugees screened in California, Colorado, and Illinois 
from 2010–2013, 1.5% were positive for syphilis infection (Figure 12). For more information on syphilis 
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screening for Congolese refugees, refer to the Health Conditions to Consider in Post-Arrival Medical 
Screening of Congolese Refugees:Syphilis section of this profile. 
Chlamydia and Gonorrhea 
Chlamydia and gonorrhea were not found to be common infections among Congolese refugees resettled 
into the United States. Among 2,355 Congolese refugees screened in California, Colorado, and Illinois 
from 2010–2013, 2.6% tested positive for chlamydia and 0% were positive for gonorrhea (Figure 12). For 
more information on chlamydia and gonorrhea screening for Congolese refugees, refer to the Health 
Conditions to Consider in Post-Arrival Medical Screening of Congolese Refugees: Chlamydia and 




In early 2014, the International Organization for Migration (IOM) noted high rates of splenomegaly in 
refugees undergoing screening in Uganda. Cases were reported to be primarily asymptomatic, clustered in 
families, and exclusively occurring in refugees from Democratic Republic of the Congo (DRC). This 
clinical finding was particularly common in the Kyangwali, a Resettlement Camp in Uganda, where it 
was noted that 16% of refugees had splenic enlargement. IOM, with the assistance of the U.S. Centers for 
Disease Control and Prevention (CDC), began offering additional diagnostic testing and empiric 
treatment for refugees with palpable splenomegaly during pre-departure medical examinations to better 
understand the increase in cases. Clinical evaluation is currently taking place to identify with certainty the 
etiology and to ascertain potential causes such as acute malarial, schistosomiasis, leishmaniasis, hepatic 
disease (i.e., hepatitis C), and non-infectious etiologies (such as thalassemias).  
Although etiology is currently unknown, one potential cause is chronic, repeated infections with malaria 
(when severe, termed “Hyperreactive Malaria Splenomegaly (HMS) Syndrome”). While the investigation 
is ongoing, all refugees with positive malaria tests are receiving treatment for acute malaria. In addition, 
all refugees will be presumptively treated with artemether-lumefantrine (which will treat blood stage 
malaria parasite) immediately before departure to the United States.  
Malaria-associated splenomegaly and HMS are complications of recurrent malaria infections. Although 
the specific pathophysiology is unknown, evidence suggests that repeated exposure to malaria antigens 
elicits an exaggerated immune response, excessive IgM production, and eventual splenic deposition that 
results in splenomegaly. Patients with HMS may not have active signs of malaria or detectable parasite in 
their blood if tested for malaria (e.g., may have negative blood smears or rapid malaria tests [RDTs]). 
Symptoms of HMS can be quite variable and may consist solely of abdominal fullness or palpable 
splenomegaly. However, the degree of splenomegaly, at times, can be severe, reaching lengths of 20 cm 
and leading to fatal complications, if left unmanaged. Fatal complications include splenic rupture 
following minor trauma or secondary bacterial infections due to underlying hematological abnormalities 
(i.e., severe hypersplenism, leukopenia). 
All refugees who underwent HMS therapy prior to departure should receive follow-up testing after 
arriving in the United States. These patients should receive laboratory testing, including repeat IgM 




testing and repeat ultrasonography. In addition, all refugees who have presumed malaria-associated 
splenomegaly or HMS should be tested for G6-PD. If the G6-PD is normal, patients should be treated 
with a 2-week course of primaquine for the potential hepatic phase of non-falciparum malaria. Persons 
with a large spleen should also be reminded not to participate in physical activities that can cause trauma 
(i.e., contact sports).  
Based on the results of the ongoing investigation, CDC may issue additional recommendations for the 
monitoring and/or treatment of relocated refugees with HMS. For further information, see CDC 
guidelines regarding diagnostic testing for malaria, as well as post-arrival guidance on the management of 
malaria and its complications in refugee populations: 
Anemias 
As in other refugee populations, anemia in the Congolese is frequently multifactorial. In contrast, 
however, Congolese are expected to have higher rates of sickle cell disease (SCD) and trait. The DRC, 
along with Uganda, Cameroon, Gabon, Ghana, and Nigeria, are considered to have the highest overall 
burden of SCD in Africa (22). The overall prevalence of sickle cell anemia (SCA, including trait and 
disease) in the DRC is estimated to be between 20–30% (22). In 2010 an estimated 79% (~242,200) of 
neonates with SCA were born in sub-Saharan Africa, with 2 African countries and 1 Asian country 
(Nigeria, DRC, and India) representing 57% (~353,500) of the annual number of newborns with SCA 
globally (22). A significant number of those with SCD and its variants will experience a sickle crisis 
when they travel to even modest altitudes (>4,400 feet), and this should be considered for those moving to 
United States cities that are in higher altitudes (e.g., Denver, Salt Lake City) (23). In addition, data from a 
pilot health assessment conducted in refugee camps in Rwanda in 2012 showed that 5% of refugees had 
mild, moderate, or severe iron deficiency anemia (unpublished CDC data). Several refugee camps in 
Rwanda are located at higher elevations (>2,000m); therefore, adjustments for altitude were made by 
using WHO/CDC criteria for all locations to prevent underestimates of anemia in the Rwanda cohort. 
Cases of moderate and severe anemia were low (1% and 0.3%, respectively) after hemoglobin values 
were adjusted for gender, age, and camp elevation. For more information on anemia screening for 
Congolese refugees, refer to the Congolese Health Conditions to Consider in Post-Arrival Medical 
Screening of Congolese Refugees: Anemia section of this profile.  
Nutrition 
Data from a pilot health assessment conducted in Rwanda in 2012 showed a relatively low rate of 
malnutrition in refugees located in 3 refugee camps, as well as in urban refugees living in Kigali 
(unpublished CDC data). Of children aged 6–59 months from all Rwanda locations, 5% met the criteria 
for moderate acute malnutrition. No children in this age group had severe acute malnutrition from any 
location in Rwanda. Of children aged 5–19 years, 3% met criteria for severe acute malnutrition and 6% 
met criteria for moderate acute malnutrition. Acute malnutrition as defined by BMI was more prevalent in 
the camps than among the urban refugee population; however, 55% of adult refugees screened from the 
urban population were overweight or obese by the same index. Overall, the prevalence of malnutrition 
among children aged 6–59 months in the Rwanda cohort was lower than rates among other refugee 
groups resettling from other parts of Africa. Prevalence rates of acute malnutrition (i.e., “wasting”) in 
children 6–59 months have been as high as 12.3% and 8.2% in certain camp locations in Ethiopia and 
Kenya, respectively (26). However, since prevalence rates for moderate and severe anemia in the Rwanda 
cohort were also low (1% and 0.3%, respectively), this suggests a lower risk of overall nutritional 
deficiencies in this population than in other United States-bound refugee groups. It should be noted that 




these are Rwanda-specific data only and may not reflect the nutritional status of Congolese refugees 
resettling from other countries. 
Hypertension, Dyslipidemia, and Diabetes 
Hypertension, dyslipidemia, and diabetes are disproportionately represented in persons of African 
descent. Data from Congolese patients indicate that this population follows these trends and has high rates 
of these disorders (Figure 13) (24, 25).  
Figure 13: Non-communicable diseases as reported by Congolese refugees during overseas medical 
examinations at panel physician sites, 2008–2012 (N=4,938) 
 
Source: CDC, DGMQ,EDN 
Mental Health 
Mental health conditions in refugee populations can develop or become exacerbated due to issues related 
to acculturation and limited coping mechanisms upon resettlement. Among the 3,577 Congolese refugees 
examined by IOM physicians in the overseas medical screening exam from 2010–2012, 1% were found to 
have a mental health condition. Data in Table 2 demonstrate the most common mental health conditions 
found among Congolese refugees. These were mental retardation (0.39%); adjustment disorders (0.34%); 
schizophrenia (0.11%); mental disorder, not otherwise specified (0.08%); depression (0.06%); and 
specific developmental disorder of motor function (0.6%). Mental retardation includes cases ranging from 
mild to moderate and unspecified mental retardation. Depression includes mild, moderate, and severe 
episodes of depression without psychotic symptoms. The mental health component of the overseas 
medical screening exam is subject to limitations in the refugee setting including lack of medical history, 


































Table 2: Top disease conditions (ICD-10) under mental health disease group among Congolese 
refugees (n=3,577) screened in Burundi, Rwanda, Uganda, and Kenya, 2010–2012 
ICD-10 disease condition under mental health disease group           No. of People       Prevalence 
(%) 
Mental retardation 13 0.39% 
Reaction to severe stress and adjustment disorders 11 0.34% 
Schizophrenia 4 0.11% 
Mental disorder, not otherwise specified 3 0.8% 
Depression 2 0.6% 
Specific developmental disorder of motor function 2 0.6% 
Total 35 1.03% 
Source: IOM 
Although IOM data indicated low rates for some mental health disorders, other assessments have shown 
high rates of post-traumatic stress disorder (PTSD) among this population. The high rates of PTSD are 
due to the severe and widespread nature of personal violence and trauma Congolese refugees are reported 
to have witnessed and experienced, including Sexual Gender Based Violence. A population-based study 
conducted in the eastern DRC identified 41% of the adult population that met the symptom criteria for 
major depressive disorder (MDD), and 50% for PTSD. After extrapolation to the sampling frame 
population of the DRC, it is estimated that 3.25 million adults meet criteria for PTSD, 2.63 million meet 
criteria for MDD, and approximately 1.04 million have attempted suicide (9). 
A recent report surveying 43 local resettlement agencies serving Congolese refugees after their arrival in 
the United States suggested a high degree of mental health issues, including depression, anxiety disorder, 
substance abuse, and domestic violence (11). This report also identified at least 2 challenges in terms of 
increasing access to mental health services in the US for Congolese: (a) interpretation needs and (b) 
client’s refusal of services.  However, in a controlled trial of psychotherapy among Congolese survivors 
of sexual violence randomly assigned to either group therapy or individual support, group psychotherapy 
was found to be more effective at reducing PTSD symptoms, combined depression and anxiety 
symptoms, and improving functioning (27). This suggests that while mental health is a sensitive subject 
for Congolese, in settings where trust has been built between patient and caregiver, open discussion of 
mental health problems may be more readily achieved. 
Summary 
Because Congolese refugees have been resettled in the United States for only a limited time compared 
with other refugee populations, their health issues may not be well known. The information provided in 
this refugee health profile is intended to help resettlement agencies, clinicians, and providers understand 
the cultural background of and health issues that affect resettling Congolese refugee populations. The 
following health conditions are considered priority health conditions when caring for or assisting 
Congolese refugees: parasitic infections, malaria, mental health, and sexual- and gender-based violence. 
These health conditions represent a distinct health burden for the Congolese refugee population, although 
this population may have other health conditions as well.  
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